This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports research to validate the plasma membrane vacuolar ATPase (pmVATPase) as a therapeutic target and develop novel antibody-based treatments targeting this protein. The $237,724 award to New York University School of Medicine, effective February 21, 2025 through January 31, 2027, aims to:
- Develop antibodies that recognize and bind to the ATP6AP1 subunit of pmVATPase, which is highly expressed on the surface of cancer cells and critical for the protein's localization.
- Establish a strategy to selectively inhibit or kill cancer cells with high pmVATPase levels using the anti-ATP6AP1 antibodies.
This research seeks to advance pmVATPase as an actionable therapeutic target and enable the development of novel antibody-based cancer treatments that can selectively target this protein on the cell surface while minimizing toxicity to normal cells.
Generated 3/25/25, 3:03 AM